<DOC>
	<DOCNO>NCT00413504</DOCNO>
	<brief_summary>To determine whether fondaparinux monotherapy without warfarin effective safe long-term ( 90 day ) treatment DVT and/or PE , thus gain new long-term experience data use fondaparinux .</brief_summary>
	<brief_title>Fondaparinux Monotherapy DVT and/or Pulmonary Embolism</brief_title>
	<detailed_description>Background Significance : Warfarin usually prescribe manage long-term anticoagulation deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) . However 5 % patient unable tolerate warfarin safely effectively anticoagulated . Some reason discontinue warfarin anticoagulation switch patient parenteral anticoagulation follow : 1 . Recurrent venous thromboembolism despite anticoagulation warfarin 2 . Clinically important bleeding complication due warfarin 3 . Inability achieve target International Normalized Ratio ( INR ) warfarin 4 . Nonbleeding side effect warfarin , hair loss rash . These patient tolerate respond adequately warfarin usually manage `` off-label '' twice-daily enoxaparin injection monotherapy . The approved duration treatment DVT PE fondaparinux 5 9 day `` bridge '' warfarin . Until , study investigate use fondaparinux 26 day treatment PE 10 day treatment DVT . Treatment dose twice-daily enoxaparin Food Drug Administration ( FDA ) approve 5 14 day `` bridge '' treatment acute DVT and/or PE patient warfarin . Fondaparinux synthetic antithrombotic agent specific anti-factor Xa activity . Its pharmacokinetic property allow simple , fixed-dose , daily regimen subcutaneous injection , without need dose adjustment base laboratory monitoring . Fondaparinux available 3 treatment dos prescribe every 24 hour base patient 's weight : 5 mg patient weigh less 50 kg , 7.5 mg patient weigh 50 100 kg , 10 mg patient weigh 100 kg available prefilled syrinx . Also , fondaparinux cross react heparin-induced platelet antibody , heparin-induced thrombocytopenia never document fondaparinux . The MATISSE Investigators show once-daily , subcutaneous administration fondaparinux least 5 day 2 consecutive INRs great 2.0 `` bridge '' warfarin least effective safe adjusted-dose , intravenous administration unfractionated heparin `` bridge '' warfarin initial treatment hemodynamically stable patient pulmonary embolism . During 3-month follow , 42 1103 patient randomly assign receive fondaparinux ( 3.8 percent ) recurrent thromboembolic event , compare 56 1110 patient randomly assign receive unfractionated heparin ( 5.0 percent ) . Major bleeding occur 1.3 percent patient treat fondaparinux 1.1 percent treat unfractionated heparin . Mortality rate three month similar two group . In another randomized double-blinded trial MATISSE Investigators , patient randomize fondaparinux daily versus enoxaparin twice daily least 5 day 2 consecutive INRs great 2.0 `` bridge '' warfarin initial treatment acute symptomatic DVT . Fondaparinux find effective safe twice-daily enoxaparin 3-month follow period . 43 ( 3.9 % ) 1098 patient randomly assign fondaparinux recurrent thromboembolic event compare 45 ( 4.1 % ) 1107 patient randomly assign enoxaparin . Major bleeding occur 1.1 % patient receive fondaparinux 1.2 % patient receive enoxaparin . Mortality rate 3.8 % 3.0 % , respectively . These two MATISSE trial total 4418 patient lead FDA approval fondaparinux treatment acute symptomatic DVT PE `` bridge '' warfarin . In investigator-initiated trial , conduct cohort study daily fondaparinux monotherapy without warfarin 90-day management DVT and/or PE patient unable tolerate respond adequately warfarin . Research Design Methods : This cohort study sample size 30 patient Brigham Women 's Hospital history DVT and/or PE intolerant warfarin respond warfarin . During study 3 visit day zero , week 6 , day 90 . Patients monitor closely bleeding complication . During visit , blood drawn platelet count , renal function , hematocrit , transaminase level . Primary endpoint 1 . Recurrent acute symptomatic DVT confirm venous ultrasound and/or CT scan 2 . Recurrent acute symptomatic PE confirm chest CT scan 3 . Major hemorrhage define spinal , retroperitoneal intracranial bleeding , drop hemoglobin ≥2g/dl transfusion ≥2U surgical medical intervention , death related bleeding Secondary endpoint Comparison Day Zero , 6 week , Day 90 platelet count , renal function , hematocrit transaminase level Drug Dose : Patients enrol study receive weight-based dose fondaparinux monotherapy 90 day treatment DVT and/or PE . Weight &lt; 50 kg - 5 mg daily Weight 50 - 100 kg - 7.5 mg daily Weight &gt; 100 kg - 10 mg daily Biostatistical Analysis : Descriptive statistic perform use age , gender , indication long-term anticoagulation .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>1 . Recurrent venous thromboembolism despite anticoagulation warfarin ( Or ) 2 . Clinically important bleeding complication due warfarin ( Or ) 3 . Inability achieve target INR warfarin ( Or ) 4 . Nonbleeding side effect warfarin , hair loss , rash , purple toe syndrome ( Or ) 5 . Patient cancer monotherapy parenteral anticoagulation DVT and/ PE 6 . Require least 90 day anticoagulation 7 . Require anticoagulation objectively confirm DVT and/or PE 8 . Age great 18 year 9 . Written inform consent 1 . Patients renal insufficiency , define creatinine &gt; 1.5 mg/dl 2 . Patients anticoagulation agent deem unsafe due bleeding risk . 3 . Pregnancy 4 . Known hypersensitivity fondaparinux</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Fondaparinux</keyword>
	<keyword>Monotherapy</keyword>
	<keyword>Deep Vein thrombosis</keyword>
	<keyword>Pulmonary Embolism</keyword>
	<keyword>Anticoagulation</keyword>
</DOC>